# A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379

> **NCT06204107** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 28 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** CKD-379(Empagliflozin+sitagliptin+metformin) Test drug
- **DRUG:** CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug

## Key facts

- **NCT ID:** NCT06204107
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-21
- **Primary completion:** 2023-12-06
- **Final completion:** 2023-12-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06204107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06204107, "A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06204107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*